Literature DB >> 15589427

Current management of gout in patients unresponsive or allergic to allopurinol.

Thomas Bardin1.   

Abstract

The manifestations of gout can be abolished permanently by lifelong urate-lowering therapy maintaining serum urate levels under 360 mmol/l, as this ensures dissolution of pathogenic crystals of monosodium urate monohydrate. Benzbromarone has been withdrawn from the market, leaving allopurinol as the only urate-lowering drug readily available in France. Allopurinol may induce unacceptable side effects, and in patients with dose-limiting renal failure it may not be sufficiently effective. Because allopurinol can induce serious side effects when given concomitantly with purine antimetabolites, it is contraindicated in organ transplant recipients. In patients who cannot tolerate allopurinol, dietary treatment, discontinuation of diuretic agents, and use of losartan or fenofibrate to treat concomitant hypertension or dyslipidemia, respectively, may ensure adequate control of serum urate levels. Desensitization to allopurinol can be attempted in patients with mild cutaneous hypersensitivity reactions but is difficult to perform and rarely used. Uricosuric agents may be helpful in patients with normal or diminished urate excretion. Probenecid is available in France from hospital pharmacies, and benzbromarone can be prescribed via a time-limited authorization procedure. Rasburicase, an Aspergillus urate oxidase produced by genetic engineering, is indicated to prevent acute hyperuricemia induced by chemotherapy for hematological malignancies. Factors that limit the use of rasburicase include the absence of a marketing authorization, the need for parenteral administration, and the absence of validated treatment schedules. Patients with renal failure precluding the use of effective allopurinol dosages are good candidates for benzbromarone therapy. Organ transplant recipients can be given benzbromarone, within the current restrictions to its use; alternatively, mycophenolate mofetil can be substituted for calcineurin inhibitors, which elevate serum urate levels, or for azathioprine, which contraindicates the use of allopurinol.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15589427     DOI: 10.1016/j.jbspin.2004.07.006

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  12 in total

1.  [Allopurinol-induced hypersensitivity syndrome resulting in death].

Authors:  Sören Laurisch; Maren Jaedtke; Reyhan Demir; Sajoscha A Sorrentino; Jan T Kielstein; Hans-Oliver Rennekampff; Peter M Vogt; Gerd P Meyer; Martin Fuchs; Gunnar Klein; Hartmut Drexler; Bernhard Schieffer; L Christian Napp
Journal:  Med Klin (Munich)       Date:  2010-04

Review 2.  Pathophysiology, clinical presentation and treatment of gout.

Authors:  Gim Gee Teng; Raj Nair; Kenneth G Saag
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  New developments in clinically relevant mechanisms and treatment of hyperuricemia.

Authors:  Susan J Lee; Robert A Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

4.  Site-specific incorporation of unnatural amino acids into urate oxidase in Escherichia coli.

Authors:  Mingjie Chen; Lei Cai; Zhengzhi Fang; Hong Tian; Xiangdong Gao; Wenbing Yao
Journal:  Protein Sci       Date:  2008-07-02       Impact factor: 6.725

Review 5.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 6.  Febuxostat.

Authors:  Philip I Hair; Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.

Authors:  Lisa Cammalleri; Mariano Malaguarnera
Journal:  Int J Med Sci       Date:  2007-03-02       Impact factor: 3.738

8.  A Novel Multi-Epitope Vaccine Based on Urate Transporter 1 Alleviates Streptozotocin-Induced Diabetes by Producing Anti-URAT1 Antibody and an Immunomodulatory Effect in C57BL/6J Mice.

Authors:  Yanjie Ma; Huimin Cao; Zhixin Li; Jinzhi Fang; Xiaomin Wei; Peng Cheng; Rui Jiao; Xiaoran Liu; Ya Li; Yun Xing; Jiali Tang; Liang Jin; Taiming Li
Journal:  Int J Mol Sci       Date:  2017-10-16       Impact factor: 5.923

9.  Synergistic Uric Acid-Lowering Effects of the Combination of Chrysanthemum indicum Linne Flower and Cinnamomum cassia (L.) J. Persl Bark Extracts.

Authors:  Young-Sil Lee; Eunjung Son; Seung-Hyung Kim; Yun Mi Lee; Ohn Soon Kim; Dong-Seon Kim
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-09       Impact factor: 2.629

10.  DKB114, A Mixture of Chrysanthemum Indicum Linne Flower and Cinnamomum Cassia (L.) J. Presl Bark Extracts, Improves Hyperuricemia through Inhibition of Xanthine Oxidase Activity and Increasing Urine Excretion.

Authors:  Young-Sil Lee; Seung-Hyung Kim; Heung Joo Yuk; Dong-Seon Kim
Journal:  Nutrients       Date:  2018-09-28       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.